Abivax Announces a Change to the Composition of its Board of Directors
Abivax SA (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announced that Dr. Philippe Pouletty, representative of Truffle Capital, tendered his resignation as director of the Company effective on December 31, 2024. Dr. Philippe Pouletty’s decision is directly related to his appointment last week as Chairman and acting Chief Executive Officer of a French listed biotechnology company in the field of plastics recycling. Dr. Pouletty, also CEO of Truffle Capital, was Chairman of the Board of Directors of Abivax from the inception of the Company in December 2013 until August 2022 and has continued as a Board member since then.
HR Tech Insights: Coinmotion Appoints Two New Members to its Strategic Board
Philippe Pouletty, MDsaid: “It is a great pride for me and Truffle Capital to have founded Abivax and to have contributed to the development of obefazimod for over a decade. I am convinced that Abivax, led by a strong CEO, management team, and board of directors, has the potential to help hundreds of thousands of patients suffering from severe inflammatory diseases. I expect Truffle Capital to continue to be a great supporter of Abivax as a major shareholder through the next several inflection points, including the expected Phase 3 ABTECT data readout in 2025.”
HR Tech Insights: Betterworks: DEIB Dashboards With Advanced Analytics Launched
Sylvie Grégoire, PharmD, Chair of the Board of Abivax:“On behalf of the Board of Directors of Abivax I would like to thank Philippe for his numerous and significant contributions to Abivax over the past several years. As a founder and former chairman, Dr. Pouletty has played a pivotal role in guiding the Company to the forefront of therapeutic innovation, particularly in the development of Abivax’s lead drug candidate, obefazimod, which is now in Phase 3 clinical trials for ulcerative colitis. We will initiate a search to complete the board composition with a strong candidate to contribute to the advancement of Abivax’s late-stage pipeline in IBD.”
HR Tech Insights: Norfolk Southern Names Ann A. Adams Chief Human Resources Officer
Source – GlobeNewswire
Your source for breaking news in HR innovation The HRTech Media Room is the dedicated news and updates division of HR Technology Insights, focused exclusively on delivering the latest market intelligence from the world of HR technology. With a pulse on emerging trends, product launches, funding updates, strategic partnerships, and industry movements, our team ensures you stay informed and ahead of the curve. Backed by a team of researchers and editors with deep expertise in HR tech and enterprise solutions, the Media Room brings you timely, verified, and concise reporting designed for busy HR professionals and tech decision-makers. Whether it's a breakthrough in AI-powered recruitment or a disruptive HR SaaS startup entering the scene, we cover what matters—fast. Stay informed with HRTech Media Room—your trusted lens on the dynamic world of HR innovation.
Xerox agrees to acquire Lexmark from Ninestar, PAG Asia, and Shanghai Shouda for $1.5 billion, including assumed liabilities.
Service Leadership Inc., announced the early findings from its highly anticipated 12th Annual IT Solution Provider Compensation Report.
